GlassScriptPhysician profile
Curtis Chow
NPI 1750461794
$2,987.84
in general payments reported to CMS, 2019-2025
26 companies · $443 in 2025
The $443 reported for 2025 was more than what 76% of Occupational Health (Nurse Practitioner) providers received nationally (typical 2025 total: $136).
See the full distribution for Occupational Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $283 · 2023: $546 · 2024: $829 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $603.08 | 2021-2024 | Breztri, Tezspire, Airsupra |
| Novo Nordisk INC | $342.30 | 2021-2025 | Wegovy, Ozempic |
| Esperion Therapeutics, INC. | $193.47 | 2021 | |
| Lilly USA, LLC | $180.01 | 2021-2024 | Zepbound, Jardiance |
| Medtronic, INC. | $167.75 | 2021-2025 | Venaseal |
| Glaxosmithkline, LLC. | $162.34 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $141.56 | 2022-2024 | |
| Eisai INC. | $125.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $114.36 | 2024 | |
| Genzyme Corporation | $110.31 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.92 | 2021 | |
| Exact Sciences Corporation | $107.70 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $79.60 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $76.45 | 2024 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $73.97 | 2023-2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $73.06 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $69.69 | 2023-2024 | Otezla, Repatha, Prolia |
| Corcept Therapeutics | $67.31 | 2025 | Korlym |
| Coloplast Corp | $41.49 | 2023 | Restorelle |
| Abbott Laboratories | $36.93 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Organon LLC | $29.26 | 2024 | |
| Sanofi Pasteur INC. | $22.44 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.13 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $15.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.39 | 2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.